Humanized Antibody definition

Humanized Antibody means [ * ] pursuant to this Agreement by [ * ]. The term "Humanized Antibody" shall include, without limitation [ * ].
View Source
Humanized Antibody shall include, without limitation [ * ].
View Source
Humanized Antibody means an antibody that binds to Sphingosine-1-phosphate and is made by AERES under this Agreement, the antibody comprising murine complementarity determining regions (‘CDRs’ as identified in Exhibit A 1. Winter Patent”) derived from Sphingomab™ together with human framework regions, and any modifications thereof.
View Source

Examples of Humanized Antibody in a sentence

  • If [ * ] decides not to file an IND for any particular Humanized Antibody, then the provisions of Section 7.3 shall apply to that Humanized Antibody.

  • During the term of this Agreement, AERES will not assert AERES IP or Licensed Patent Rights or any of its claims to intellectual property arising out of the Research Collaboration against LPT in a manner which would prevent LPT from making, having made, using, offering for sale, selling, importing, or otherwise commercializing any Humanized Antibody produced hereunder.

  • AERES shall not, except in the event of termination of this Agreement by AERES pursuant to Paragraphs 8.4, 8.5 or 8.6 hereof, exercise any of its proprietary rights arising hereunder or otherwise restrict LPT from commercializing any Humanized Antibody produced hereunder in any manner.

  • In the event that [ * ] creates a Humanized Antibody, but decides not to proceed with an IND filing for such Humanized Antibody, then such Humanized Antibody shall be treated in the same manner as a [ * ] Product is treated under [ * ].

  • At the completion of Phase I, if requested by PROGENICS, PDL will deliver a sample of (i) a non-optimized cell line and (ii) a DNA vector (“DNA Vector”) producing the Humanized Antibody to allow PROGENICS to conduct research while PDL proceeds with Phase II of the Program.

  • Promptly following delivery of the Humanized Antibody pursuant to Section 2.02(a), PROGENICS shall also evaluate the Humanized Antibody to determine whether such antibody also possesses anti-HIV activity not less than one-third (1/3) that of the Murine Antibody (“Minimum Anti-HIV Activity”) as measured according to an HIV-1 infectivity assay that measures the extent of HIV-l replication specified in ▇▇▇▇▇▇ et.

  • PDL shall then use commercially reasonable efforts to produce another Humanized Antibody in an effort to achieve the Minimum Binding Affinity and the Minimum Anti-HIV Activity.

  • In the event that PROGENICS determines that one of the Humanized Antibodies provided by PDL meets the Minimum Binding Affinity and the Minimum Anti-HIV Activity, or is sufficiently close thereto to enable PROGENICS to proceed with the Humanized Antibody under Phase II of the Program, it shall promptly notify PDL in writing (the “Phase I Completion Notice”).

  • PDL shall own any and all inventions, discoveries, concepts and ideas, whether patentable or not, developed by employees or collaborators of PDL related to the Humanized Antibody, without prejudice, however, to the right of involved PROGENICS employees or collaborators, if any, to be named as inventors or co-inventors in accordance with applicable patent laws.

  • In the event that the second Humanized Antibody does not meet the Minimum Binding Activity and the Minimum Anti-HIV Activity or is, in PROGENICS’ sole discretion, not sufficiently close thereto to enable PROGENICS to proceed with development, then the parties shall consult in good faith in order to determine how to proceed with further development.


More Definitions of Humanized Antibody

Humanized Antibody means an antibody or immunoglobulin that contains [**]. A description of PCR, ELISA and flow cytometric assays (herein, the “F2A Assays”) to be used above are attached in an Appendix to the hTG Collaboration Agreement. THP’s and SMC’s responsibilities for performance and time frames for performance of the F2A Assays are set forth in an Appendix to the hTG Collaboration Agreement.
View Source

Related to Humanized Antibody

  • Antibody means a molecule or a gene encoding such a molecule comprising or containing one or more immunoglobulin variable domains or parts of such domains or any existing or future fragments, variants, modifications or derivatives thereof.

  • Licensed Antibody means (a) any Licensed Program Antibody and (b) any other Antibody that is a variant, fragment, derivative or other modification of a Licensed Program Antibody, that (i) Targets the Licensed Target, (ii) is made by or on behalf of Celgene or its Affiliates or Sublicensees during the Term in the course of its activities performed under this Agreement (or during the term of the Licensed Program U.S. License Agreement in the course of its activities performed thereunder) and (iii) is claimed (or was claimed in an issued Patent that has subsequently expired) as a composition of matter in a Licensed Program Patent set forth on Schedule 1.46(b), a Prothena Licensed Collaboration Patent set forth on Schedule 1.63, or Joint Program Patent (as defined in the Master Collaboration Agreement) as applicable, or any substitutions, divisionals, continuations, continuations-in-part, reissues, renewals, registrations, confirmations, re-examinations, extensions, supplementary protection certificates and the like of any such Licensed Program Patents, Prothena Licensed Collaboration Patents or Joint Program Patents (as defined in the Master Collaboration Agreement).

  • Opioid antidote means any drug, regardless of dosage amount or method of administration, which has been approved by the United States Food and Drug Administration (FDA) for the treatment of an opioid overdose. “Opioid antidote” includes, but is not limited to, naloxone hydrochloride, in any dosage amount, which is administered through nasal spray or any other FDA-approved means or methods.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Opioid antagonist means a drug that binds to opioid